Clinical trial NCT00016835: Treating Periodontal Infection: Effects on Glycemic
Official title: Treating Periodontal Infection: Effects on Glycemic Control in People With Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Periodontal Disease
Diabetes Mellitus, Type 2
Keywords: Type 2 diabetes mellitus
Glycemic control
Periodontal therapy
Lead sponsor: University of Michigan
Sponsor class: OTHER
Collaborators: name: National Institute of Dental and Craniofacial Research (NIDCR)
First posted: 2001-06-07
Enrollment: 46
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Study participants were randomized into 3 groups for the initial non-surgical treatment appointment. One group received supra-gingival scaling and placebo, one group received non-surgical periodontal supra- and sub-gingival scaling plus metronidazole and one group received non-surgical periodontal supra- and sub-gingival scaling plus doxycycline. All three groups received 3-month follow-up visits for 15 months and the group receiving supra-gingival scaling and placebo at the initial visit received supra- and sub-gingival scaling at the 9-month follow-up visit.
Primary purpose: TREATMENT

Brief summary: The purpose of this project is to obtain important preliminary data necessary to support design of a full scale, multicenter randomized clinical trial (RCT) to evaluate the effect of treating periodontal infection on glycemic control in type 2 diabetes mellitus.

Detailed description: There is compelling epidemiological and clinical evidence to suggest that periodontal infection adversely affects glycemic control in people with type 2 diabetes mellitus. The purpose of this pilot project is to obtain important preliminary data necessary to support design of a full scale, multi-center randomized clinical trial (RCT) to evaluate the effect of treating periodontal infection on glycemic control in individuals with type 2 diabetes mellitus. This current project involves treating periodontal infection to obtain estimates of changes and the variability of those changes over time in the established primary endpoint, hemoglobin A1c (HbA1c). This project will also explore use of several potential secondary endpoints including levels of periodontitis and glucose metabolism-related inflammatory mediators (TNF-alpha, IL-1-beta, IL-6), serum cholesterol, triglyceride and lipids. Subjects are randomly assigned to 1 of three possible groups for comprehensive periodontal examination, specimen collection, mechanical periodontal therapy and oral systemic antibiotics or placebo, and regular follow-up evaluations and site-specific mechanical periodontal therapy, at 3-month intervals, for approximately 15 months. Two groups receive ultrasonic scaling with local anesthesia (as needed), local antimicrobial treatment with povidone-iodine irrigation, and an oral systemic antibiotic (either doxycycline or metronidazole) at the initial treatment visit. The third group ("controls") receives a placebo and supra-gingival oral prophylaxis and ultrasonic removal of supra-gingival calculus with water irrigation at the initial treatment visit. At the 9-month follow-up visit, "controls" receive sub-gingival ultrasonic scaling with povidone-iodine irrigation.

Results from this pilot project will be used as preliminary data to support design of an immediate follow-up proposal to NIH/NIDCR for funding a multi-center RCT to evaluate the effect of treating periodontal infection on glycemic control in type 2 diabetes. If results from the full scale clinical trial provide evidence that treating periodontal infection contributes to improved glycemic control, then diagnosis and treatment of periodontal infection in subjects with type 2 diabetes could be substantiated as an important component in management of diabetes.

Eligibility criteria: Inclusion Criteria

* Subjects must be 18 years of age or older,
* have at least six natural teeth,
* have established periodontal disease (established at the screening examination),
* have a history of type 2 diabetes of at least six months with HbAlc \> 7.1%.

Exclusion Criteria

* Subjects will be excluded from the study if they are presently under the care of a periodontist;
* have had antibiotic treatment within the previous three months;
* have conditions that require antibiotic prophylaxis for dental treatment;
* have allergies to iodine, doxycycline, metronidazole, or chlorhexidine;
* have blood dyscrasias;
* are pregnant or breast feeding;
* have severe cognitive or communication impairment;
* have a cardiac pacemaker;
* are under cancer chemotherapy;
* are medically unstable or have a life expectancy of less than two years;
* are currently taking disulfiram, phenobarbital, lithium, terfenadine, astemizole, or warfarin;
* or are out of town or otherwise unavailable for more than three consecutive months of the year.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: Department of Cariology, Restorative Sciences and Endodontics
state: Michigan
Study officials:
affiliation: University of Michigan
name: George W. Taylor, DMD, Dr.PH
role: PRINCIPAL_INVESTIGATOR
References: